Abstract: The present disclosure relates to a method for feeding back reliable downlink channel state information from a receiver to a transmitter in a multi-user massive MIMO system based on a reconfigurable intelligent surface, and more particularly, to a method for the receiver to transform acquired downlink channel state information into downlink channel state information in an angle domain and compress the downlink channel state information through a compressed-sensing scheme, and then feed the compressed result back to the transmitter, and for the transmitter to acquire the reliable downlink channel state information through a recovery algorithm. According to the present disclosure, the downlink channel state information is compressed according to a compression and recovery algorithm in an mmWave environment, and only a codeword index suitable for the compressed result is fed back to the transmitter to obtain the effect of reduction in feedback overhead in the entire communication system.

Abstract: The present disclosure relates to a method for feeding back reliable downlink channel state information from a receiver to a transmitter in a multi-user massive MIMO system based on a reconfigurable intelligent surface, and more particularly, to a method for the receiver to transform acquired downlink channel state information into downlink channel state information in an angle domain and compress the downlink channel state information through a compressed-sensing scheme, and then feed the compressed result back to the transmitter, and for the transmitter to acquire the reliable downlink channel state information through a recovery algorithm. According to the present disclosure, the downlink channel state information is compressed according to a compression and recovery algorithm in an mmWave environment, and only a codeword index suitable for the compressed result is fed back to the transmitter to obtain the effect of reduction in feedback overhead in the entire communication system.

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: The present invention relates to a pyrrolobenzodiazepine derivative compound, a conjugate of the same with a ligand, and the use of the same. The pyrrolobenzodiazepine derivative compound is more stable in plasma, is stable even in circulation, and exhibits excellent efficacy. In particular, the conjugate of the pyrrolobenzodiazepine derivative compound with a ligand has a great advantage in that it is possible to target and specifically treat proliferative disease such as cancer, maximize drug efficacy, and minimize the expression of side effects since the conjugate more stably reaches the target cell and effectively exerts drug efficacy while toxicity is greatly reduced as a linker technology that allows drugs to be easily released within cancer cells and maximize drug efficacy is incorporated.

Abstract: The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.

Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Abstract: The present inventive concept relates to a method for designing an optimal analog precoder for improving frequency spectrum efficiency in a millimeter wave-based multi-user massive MIMO-based hybrid beamforming system and a hybrid beamforming system applying the same, and more specifically, to a method for designing an optimal analog precoder using an approximation technique and an iterative optimization algorithm, and a hybrid beamforming system to which the same is applied.

Abstract: The present disclosure provides a circadian rhythm correcting apparatus including a bio-illuminance measuring part configured to measure bio-illuminance of external light, a light source configured to irradiate light of a circadian wavelength band toward a retinal ganglion cell, a light source driver configured to drive the light source by supplying power to the light source, and a controller configured to control the light source driver on the basis of the bio-illuminance measured by the bio-illuminance measuring part, to correct the circadian rhythm.

Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.

Abstract: The present inventive concept relates to a method for designing an optimal analog precoder for improving frequency spectrum efficiency in a millimeter wave-based multi-user massive MIMO-based hybrid beamforming system and a hybrid beamforming system applying the same, and more specifically, to a method for designing an optimal analog precoder using an approximation technique and an iterative optimization algorithm, and a hybrid beamforming system to which the same is applied.

Abstract: Disclosed is a method of operating an air purifier by executing an artificial intelligence (AI) algorithm and/or a machine learning algorithm in a fifth generation (5G) environment connected for the Internet of Things. A method for operating an air purifier comprises determining whether an indoor situation is a situation in which protection of a filter is necessary based on sensor information from at least one sensor, in response to a determination that the indoor situation is the situation in which protection of the filter is necessary, suspending an air purifying function, and operating one or more ventilation devices. According to the present disclosure, it is possible to protect the air purifier from a situation in which a life of the filter of the air purifier can be drastically shortened.

Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.

Abstract: A multilayer seed pattern inductor includes: a magnetic body containing a magnetic material; and an internal coil part encapsulated in the magnetic body, wherein the internal coil part includes a seed pattern and a surface plating layer disposed on the seed pattern, the seed pattern being formed as two or more layers.

Abstract: A coil electronic component includes a magnetic body, wherein the magnetic body includes a substrate, and a coil part including patterned insulating films disposed on the substrate, a first plating layer formed between the patterned insulating films by plating, and a second plating layer disposed on the first plating layer.

Abstract: A thin film type inductor includes a body and external electrodes disposed on an external surface of the body. The body includes a support member and an internal coil supported by the support member, the internal coil includes an upper coil disposed on one surface of the support member and a lower coil disposed on the other surface thereof, and the upper and lower coils are connected to each other by a via electrode. Heights of a plurality of coil patterns arranged along a first virtual line are substantially equal to each other, and heights of a plurality of coil patterns arranged along a second virtual line increase toward the external surface of the body, where the first virtual line radiates from a center of a core of the body toward the via electrode and the second virtual line radiates in the opposite direction.

Abstract: The present disclosure provides a circadian illuminance measuring apparatus including: a circadian lambda filter configured to pass external light according to a circadian sensitivity curve; a light sensor configured to sense the external light has passed through the circadian lambda filter, convert the external light into an analog signal, and output the analog signal; and a circadian illuminance calculator configured to convert the analog signal into a digital signal to calculate circadian illuminance of the external light.

Abstract: A coil electronic component includes a magnetic body, wherein the magnetic body includes a substrate, and a coil part including patterned insulating films disposed on the substrate, a first plating layer formed between the patterned insulating films by plating, and a second plating layer disposed on the first plating layer.

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.